Payden Equity Income Fund Adviser Cl
PYVAX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -8.4% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 18.2% | 18.2% | 29% | 29% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 820.6% | 820.6% | 1,573.9% | 1,573.9% |
| EPS | 0.45 | 0.45 | 0.94 | 0.94 |
| % Growth | 0% | -52.1% | 0% | – |
| EPS Diluted | 0.45 | 0.45 | 0.94 | 0.94 |
| Weighted Avg Shares Out | – | – | – | – |
| Weighted Avg Shares Out Dil | – | – | – | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | -$0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 802.4% | 802.4% | 1,544.9% | 1,544.9% |